Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof ‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial

ConclusionsThe HOMAGE trial will provide insights on the effect of spironolactone on pathways that might drive progression to HF.Clinical Trial Registration: ClinicalTrials.gov NCT02556450.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Study Design Source Type: research